FDA Talent Hunt: Better To Recruit From Academia Than Industry?
This article was originally published in The Tan Sheet
CDER Oncology office head Richard Pazdur says making FDA more academic could help with retention. In addition to fewer staff than needed to complete its work, FDA’s hiring problem makes it more difficult for the agency to stay abreast of new scientific discoveries and technology.
You may also be interested in...
US FDA's Oncology Division Wants To Know About Your Pipeline, Not Just Your NDAs
Oncology Center of Excellence Director Richard Pazdur says agency invites sponsors to present about molecules under development to learn more about future plans.
FDA Reorganization Advocates Seek Senate Boost For Disease-Oriented Structure
Friends of Cancer Research proposes realignment of medical product functions by disease area without regard to modality; former commissioners give some support but new drugs Director Jenkins warns about unintended consequences that could negatively impact innovation and approvals.
Califf Supports Combo Products Pathway At Confirmation Hearing
FDA's concepts for new pathway could be ready for congressional scrutiny within a year.